Mundipharma came to Precipice to help them launch a new combination therapy for the maintenance treatment of asthma, across key European markets. We were asked to visually enhance an ‘off the shelf’ MDI (metered dose inhaler), looking at bespoke colourways and labelling, new branding, packaging and patient information that would elevate the total experience for both HCPs and asthma patients alike.
Precipice undertook detailed competitive and semiotic research plus analysis of the asthma and COPD market, identifying opportunities for design exploration. Our experienced research team tested design concepts with patients and HCPs across Europe, and a verified colour and brand strategy was established for the MDI and future Mundipharma respiratory devices.
A unique Flutiform font and ‘lung’ icon were created for use on the MDI and future devices, primary and secondary packaging, online and in corporate communications. We worked closely with Mundipharma R&D and marketing departments. Flutiform was successfully launched across Europe in 2012-2013.
Precipice continues to work with Mundipharma, using design to enhance device development, brand equity, user experience, commercial value, and bring targeted meaning to their portfolio of respiratory, oncology and pain products.
The type of people that I can always trust to deliver excellent creative solutions. Whether its brand identity, structural packaging or device design and development, Precipice always deliver to the highest quality.
Chief Marketing Officer and Board Director, Mundipharma International